{"id":"sst-0225","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SST-0225 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.","oneSentence":"SST-0225 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:04.858Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT01874626","phase":"PHASE3","title":"Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain","status":"COMPLETED","sponsor":"Strategic Science & Technologies, LLC","startDate":"2013-06","conditions":"Acute Ankle Sprain","enrollment":305},{"nctId":"NCT02597634","phase":"PHASE3","title":"Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)","status":"COMPLETED","sponsor":"Strategic Science & Technologies, LLC","startDate":"2015-11","conditions":"Delayed Onset Muscle Soreness, DOMS","enrollment":156},{"nctId":"NCT02339129","phase":"PHASE2","title":"Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness","status":"COMPLETED","sponsor":"Strategic Science & Technologies, LLC","startDate":"2014-11","conditions":"Delayed Onset Muscle Soreness","enrollment":72},{"nctId":"NCT01986660","phase":"PHASE1","title":"Open-Label, Maximum-Dose Pharmacokinetic Study of 7.5% Ibuprofen Cream (SST-0225) in Healthy Adults","status":"COMPLETED","sponsor":"Strategic Science & Technologies, LLC","startDate":"2013-10","conditions":"Healthy","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Topical Ibuprofen Cream"],"phase":"phase_3","status":"active","brandName":"SST-0225","genericName":"SST-0225","companyName":"Strategic Science & Technologies, LLC","companyId":"strategic-science-technologies-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SST-0225 is a topical ibuprofen cream, classified as a small molecule. It is being studied for the treatment of pain associated with acute ankle sprain and other conditions such as delayed onset muscle soreness.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}